enGene Therapeutics Inc. Earnings Per Share (Basic)
enGene Therapeutics Inc. (ENGN) reported Earnings Per Share (Basic) of -$0.47 per share for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-09-08
- enGene Therapeutics Inc. earnings per share, basic for the quarter ending 2026-07-31 was -$0.47.
- enGene Therapeutics Inc. earnings per share, basic for the quarter ending 2026-04-30 was -$0.43.
- enGene Therapeutics Inc. earnings per share, basic for the quarter ending 2026-01-31 was $0.44, a 8.33% decline year-over-year.
- enGene Therapeutics Inc. earnings per share, basic for the quarter ending 2025-10-31 was -$0.74.
- enGene Therapeutics Inc. earnings per share, basic for fiscal 2025 was $2.29, a 56.85% increase from fiscal 2024.
- enGene Therapeutics Inc. earnings per share, basic for fiscal 2024 was $1.46, a 99.03% decline from fiscal 2023.
- enGene Therapeutics Inc. earnings per share, basic for fiscal 2023 was $151.22, a 241.35% increase from fiscal 2022.
- enGene Therapeutics Inc. earnings per share, basic for fiscal 2022 was $44.30.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | -$0.47 10-Q · filed 2026-09-08 | -$0.90 derived: net income ÷ weighted average shares · filed 2026-09-08 | -$1.34 10-Q · filed 2026-09-08 | -$2.02 derived: net income ÷ weighted average shares · filed 2026-09-08 | |||
| 2026-04-30 | -$0.43 10-Q · filed 2026-06-15 | -$0.88 10-Q · filed 2026-06-15 | -$1.56 derived: net income ÷ weighted average shares · filed 2026-06-15 | -$2.12 derived: net income ÷ weighted average shares · filed 2026-09-08 | |||
| 2026-01-31 | $0.44 10-Q · filed 2026-03-09 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-03-09 | -$1.71 derived: net income ÷ weighted average shares · filed 2026-09-08 | -$2.22 derived: net income ÷ weighted average shares · filed 2026-09-08 | |||
| 2025-10-31 | -$0.74 derived: net income ÷ weighted average shares · filed 2025-12-22 | -$1.31 derived: net income ÷ weighted average shares · filed 2026-09-08 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-09-08 | $2.29 10-K · filed 2025-12-22 | |||
| 2025-07-31 | -$0.57 10-Q · filed 2026-09-08 | $0.57 10-Q · filed 2025-09-11 | -$1.07 derived: net income ÷ weighted average shares · filed 2026-09-08 | -$1.56 10-Q · filed 2026-09-08 | $1.56 10-Q · filed 2025-09-11 | -$1.92 derived: net income ÷ weighted average shares · filed 2026-09-08 | |
| 2025-04-30 | -$0.51 10-Q · filed 2026-06-15 | $0.51 10-Q · filed 2025-06-12 | -$0.99 10-Q · filed 2026-06-15 | $0.99 10-Q · filed 2025-06-12 | -$1.35 derived: net income ÷ weighted average shares · filed 2026-06-15 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-06-15 | |
| 2025-01-31 | $0.48 10-Q · filed 2026-03-09 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-03-09 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-03-09 | -$1.54 derived: net income ÷ weighted average shares · filed 2026-03-09 | |||
| 2024-10-31 | -$0.34 derived: net income ÷ weighted average shares · filed 2025-12-22 | -$0.66 derived: net income ÷ weighted average shares · filed 2025-12-22 | -$1.04 derived: net income ÷ weighted average shares · filed 2025-12-22 | $1.46 10-K · filed 2025-12-22 | |||
| 2024-07-31 | $0.32 10-Q · filed 2025-09-11 | -$0.70 derived: net income ÷ weighted average shares · filed 2025-09-11 | $1.12 10-Q · filed 2025-09-11 | -$4.59 derived: net income ÷ weighted average shares · filed 2025-09-11 | |||
| 2024-04-30 | $0.38 10-Q · filed 2025-06-12 | $0.82 10-Q · filed 2025-06-12 | -$5.18 derived: net income ÷ weighted average shares · filed 2025-06-12 | -$7.20 derived: net income ÷ weighted average shares · filed 2025-06-12 | |||
| 2024-01-31 | $0.46 10-Q · filed 2025-03-10 | -$7.89 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$12.23 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$16.88 derived: net income ÷ weighted average shares · filed 2025-03-10 | |||
| 2023-10-31 | -$117.92 derived: net income ÷ weighted average shares · filed 2024-12-19 | -$127.05 derived: net income ÷ weighted average shares · filed 2024-12-19 | -$136.90 derived: net income ÷ weighted average shares · filed 2024-12-19 | $151.22 10-K · filed 2024-12-19 | |||
| 2023-07-31 | $8.55 10-Q · filed 2024-09-10 | -$17.84 derived: net income ÷ weighted average shares · filed 2024-09-10 | $30.77 10-Q · filed 2024-09-10 | ||||
| 2023-04-30 | $9.30 10-Q · filed 2024-06-14 | $22.19 10-Q · filed 2024-06-14 | |||||
| 2023-01-31 | $13.29 10-Q · filed 2024-03-11 | ||||||
| 2022-10-31 | $44.30 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |